Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome

Sabine Hartlieb(German Cancer Research Center), Lina Sieverling(German Cancer Research Center), Michal Nadler-Holly(Max Delbrück Center), Matthias Ziehm(Max Delbrück Center), Umut H. Toprak(German Cancer Research Center), Carl Herrmann(Heidelberg University), Naveed Ishaque(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Konstantin Okonechnikov(German Cancer Research Center), Moritz Gartlgruber(German Cancer Research Center), Young‐Gyu Park(German Cancer Research Center), Elisa M. Wecht(German Cancer Research Center), Larissa Savelyeva(German Cancer Research Center), Kai‐Oliver Henrich(German Cancer Research Center), Carolina Rosswog(University Hospital Cologne), Matthias Fischer(University of Cologne), Barbara Hero(University of Cologne), David Jones(German Cancer Research Center), Elke Pfaff(German Cancer Research Center), Olaf Witt(German Cancer Research Center), Stefan M. Pfister(German Cancer Research Center), Richard Volckmann(Amsterdam University Medical Centers), Jan Köster(Amsterdam University Medical Centers), Katharina Kiesel(German Cancer Research Center), Karsten Rippe(German Cancer Research Center), Sabine Taschner‐Mandl(St Anna Children's Hospital), Peter F. Ambros(St Anna Children's Hospital), Benedikt Brors(German Cancer Research Center), Matthias Selbach(Max Delbrück Center), Lars Feuerbach(German Cancer Research Center), Frank Westermann(German Cancer Research Center)
Nature Communications
February 24, 2021
Cited by 112Open Access
Full Text

Abstract

Telomere maintenance by telomerase activation or alternative lengthening of telomeres (ALT) is a major determinant of poor outcome in neuroblastoma. Here, we screen for ALT in primary and relapsed neuroblastomas (n = 760) and characterize its features using multi-omics profiling. ALT-positive tumors are molecularly distinct from other neuroblastoma subtypes and enriched in a population-based clinical sequencing study cohort for relapsed cases. They display reduced ATRX/DAXX complex abundance, due to either ATRX mutations (55%) or low protein expression. The heterochromatic histone mark H3K9me3 recognized by ATRX is enriched at the telomeres of ALT-positive tumors. Notably, we find a high frequency of telomeric repeat loci with a neuroblastoma ALT-specific hotspot on chr1q42.2 and loss of the adjacent chromosomal segment forming a neo-telomere. ALT-positive neuroblastomas proliferate slowly, which is reflected by a protracted clinical course of disease. Nevertheless, children with an ALT-positive neuroblastoma have dismal outcome.


Related Papers

No related papers found

Powered by citation graph analysis